Cymerus mesenchymal stem cells (MSCs), Cynata Therapeutics’ experimental cell therapy, significantly lowered the levels of pro-inflammatory and pro-scarring molecules in the lungs of a mouse model of idiopathic pulmonary fibrosis (IPF), the company announced. The “highly potent” therapy also was shown to significantly reduce immune cell infiltration, and the…
Cymerus MSCs Ease Inflammation, Show Promise for Treating IPF
Prior to my diagnosis of idiopathic pulmonary fibrosis in 2017, my day started the same way almost every morning. I’d pick up my smartphone and see how the markets performed overnight. Then I’d look for an expected opening, based on the overseas markets. Since my diagnosis, I no longer…
Mesenchymal stem cells (MSCs) grown in three-dimension (3D) conditions produce tiny extracellular vesicles (EVs) that do not retain the anti-scarring and anti-inflammatory properties seen when they are derived from MSCs grown in two dimensions (2D), a study shows. These findings, obtained from treating a mouse model of pulmonary fibrosis…
The experimental oral therapy AMP945, from Amplia Therapeutics, is as effective as the approved therapy Ofev (nintedanib) at reducing tissue scarring, or fibrosis, in a mouse model of idiopathic pulmonary fibrosis (IPF), the company said. In addition, findings from an already completed Phase 1 trial in healthy…
Almost 30 hours after my bilateral lung transplant, it was time for me to be extubated and take my first solo breath with my new lungs. My wife, Susan, was at my bedside, along with several nurses. In a video of that day last July, you can hear Susan ask…
The National Organization for Rare Disorders’ (NORD) “Living Rare, Living Stronger Patient and Family Forum” is back in person on June 26 for a day of learning and networking in Cleveland, Ohio. The event, which brings together the rare disease community, will take place at the InterContinental Cleveland Conference…
This time a year ago was very different for my wife, Susan, and me. My idiopathic pulmonary fibrosis (IPF) was no longer stable, but progressing. Susan was confident I wouldn’t make it to Christmas. Upon exertion, I needed over 7 liters per minute (lpm) of supplemental oxygen. Exertion…
I never thought I’d take for granted the caregiving I receive from my daughter, at least not on purpose. But that’s exactly what I was doing. I knew I could count on her on the days I needed someone to drive me to my appointments, for instance, because when my…
Inconsistent results in the final planned preclinical study of NXP002, Nuformix’s experimental inhaled therapy for idiopathic pulmonary fibrosis (IPF), delayed completion of the preclinical data package needed for a potential advancement into clinical trials. The U.K.-based company, through an outsourced contract research organization (CRO), now plans to conduct additional…
Accord Healthcare has released a generic version of Esbriet (pirfenidone) for people in the U.S. with idiopathic pulmonary fibrosis (IPF). First approved by the U.S. Food and Drug Administration (FDA) in January, the treatment is now available and ready to be shipped, according to Accord. “We’re proud…
